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Abstract
Objective. The aim was to describe direct health-care costs for adults with SLE in the UK over time
and by disease severity and encounter type.
Methods. Patients aged 18 years with SLE were identified using the linked Clinical Practice
Research Datalink–Hospital Episode Statistics database from January 2005 to December 2017.
Patients were classified as having mild, moderate or severe disease using an adapted claims-based al-
gorithm based on prescriptions and co-morbid conditions. We estimated all-cause health-care costs
and incremental costs associated with each year of follow-up compared with a baseline year, adjusting
for age, sex, disease severity and co-morbid conditions (2017 UK pounds).
Results. We identified 802 patients; 369 (46.0%) with mild, 345 (43.0%) moderate and 88 (11.0%) se-
vere disease. The mean all-cause cost increased in the 3 years before diagnosis, peaked in the first
year after diagnosis and remained high. The adjusted total mean annual increase in costs per patient
was £4476 (95% CI: £3809, £5143) greater in the year of diagnosis compared with the baseline year
(P< 0.0001). The increase in costs per year was 4.7- and 1.6-fold higher among patients with severe
SLE compared with those with mild and moderate SLE, respectively. Primary care utilization was the
leading component of costs during the first year after diagnosis.
Conclusion. The health-care costs for patients with SLE in the UK are substantial, remain high after
diagnosis and increase with increasing severity. Future research should assess whether earlier diagno-
sis and treatment might reduce disease severity and associated high health-care costs.
Key words: SLE and autoimmunity; health economics; primary care rheumatology; DMARDs;
immunosuppressants
Key messages
. The direct costs of health care for patients with SLE in the UK are substantial.
. The cost to manage patients with moderate and severe SLE doubled 10 years after diagnosis.
. Patients with SLE have increasingly high health-care costs driven by primary care and prescription drugs.
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SLE is a chronic inflammatory autoimmune disease
characterized by alternating periods of increased dis-
ease activity, SLE flares, disease inactivity and remis-
sion. SLE affects multiple organs, including the skin,
musculoskeletal, renal, pulmonary and nervous systems,
leading to a wide range of clinical manifestations [1].
Common co-morbidities include cardiovascular disease
[2, 3], stroke [4], osteoporosis [5] and infection [6].
Involvement of the renal system, referred to as LN [7],
occurs in 60% of patients [8]. Organ damage in lupus
can occur as a direct consequence of the disease or
can be associated with long-term CS treatment [9–12],
which offers rapid symptom relief and effective short-
term disease control [13] but is associated with signifi-
cant adverse effects. The high prevalence of SLE-
related co-morbidities and the adverse effects associ-
ated with treatment can result in significant health-care
resource utilization and costs. SLE has been associated
with high health-care utilization and costs in several
countries [12, 14–16]; however, evidence is currently lim-
ited in the UK. Furthermore, long-term longitudinal
trends in health-care utilization and costs among
patients with SLE are lacking.
We assessed the health-care utilization (primary care,
hospitalizations, outpatient visits and selected prescrip-
tion drugs) and costs among patients with SLE over a
13-year period (2005–2017), using population-based
data for the UK from the linked Clinical Practice
Research Datalink (CPRD) and Hospital Episode
Statistics (HES) database.
Methods
Study design and data
This study adopted an observational, retrospective co-
hort design using the UK CPRD- and HES-linked health-
care administrative database and the Office for National
Statistics mortality files between 1 January 2005 and 31
December 2017. The CPRD has been used previously to
describe the epidemiology of SLE in the UK [3, 17–27].
It contains routinely collected primary care medical
records data for 5.5 million registered patients from
590 general practices covering 8% of the UK popula-
tion and has been shown broadly to be representative
of the demographic distribution of the UK population.
Linkage to HES is possible for approximately half of
patients in the CPRD primary care database. Hospital
data on the length, type, reasons and current diagnoses
for all UK National Health Service (NHS) inpatient hospi-
tal admissions and outpatient clinic attendances were
captured regardless of payer (private or government) or
geographical residency of the patient [28]. Approval for
this study was granted by the Independent Scientific
Advisory Committee for Medicines and Healthcare prod-
ucts Regulatory Agency on 8 March 2018
(CPRD00023132 PROTOCOL 17_281R).
Study population
Adult patients aged 18 years and older who had a veri-
fied SLE diagnosis in the linked CPRD–HES database
during the inclusion period were included in the study.
Patients were required to have 12 months of prior his-
tory in the CPRD GOLD database without a diagnosis of
SLE to confirm an incident diagnosis. Patients with a
first diagnosis (index date) between 1 January 2005 and
31 December 2017 with 12 months of follow-up were
selected.
Identification of SLE was based on the presence of
one or more definitive diagnostic read codes in CPRD
GOLD, confirmed by using International Classification of
Diseases, 10th Revision (ICD-10) diagnosis codes in the
HES data, by evidence of referral to a rheumatologist, or
by treatment with one or more SLE-targeted prescription
medications (including oral prednisolone, immunosup-
pressive therapy and antimalarials) using an algorithm
modified from Nightingale et al. [23] (Supplementary
Table S1 and S2, available at Rheumatology Advances
in Practice online). An index date was assigned corre-
sponding to the earliest SLE diagnosis anywhere in the
linked CPRD–HES dataset. Prescriptions for SLE treat-
ment alone were not considered enough to identify SLE
incidence; however, if an SLE-specific prescription was
identified before the first SLE diagnosis, the time of that
prescription was taken to be the index diagnosis date.
Patients were excluded if they had read codes indi-
cating cutaneous, drug-induced or discoid lupus rather
than systemic lupus; if they did not have a definite code
anywhere in their CPRD record or in HES to confirm di-
agnosis; or if they transferred out of the practice before
the index event date.
Study time line
Patients were followed for 3 years before diagnosis (i.e.
before their index diagnosis date) until the earliest of the
following events: end of study period; leaving the data-
base/date of patient’s last observed visit; or death.
Person-time denominators were used to handle the
varying lengths of follow-up of patients.
Assessment of disease severity
Disease severity (mild, moderate or severe) was defined
using an algorithm adapted from a US retrospective, ob-
servational study [16], which combined SLE medications
with SLE-related conditions (Supplementary Table S3,
available at Rheumatology Advances in Practice online).
The assigned disease severity was the highest severity
experienced by a patient during a 1-year baseline period
(12 months before index). SLE disease severity was de-
fined as mild, moderate or severe. SLE was categorized
as severe if treatment included CYC or an oral CS (pred-
nisone-equivalent) prescription of 60 mg/day, or diag-
nosis of a severe co-morbid condition (e.g. end-stage
renal disease, arterial/venous thrombosis). A moderate
SLE category was assigned if treatment did not include
CYC or oral CSs 60 mg/day, if there was a presence
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of a diagnosis of a moderate co-morbid condition (e.g.
nephritis, haemolytic anaemia), or if treatment included
an oral CS prescription of 7.5 to <60 mg/day or use of
an immunosuppressive agent (excluding CYC). When
patients did not meet criteria for moderate or severe dis-
ease, they were assigned mild SLE.
Assessment of health-care utilization and costs
Mean all-cause health-care costs were estimated using
standard unit costing methods [29, 30]. We focused on
all-cause health-care costs in order to capture the cost
associated with treatment of SLE, related co-morbidities
and adverse effects from treatment. Primary care costs
were calculated by multiplying the duration of each con-
sultation by the average cost per minute based on a
comprehensive estimate of general practice expenses
[31]. Outpatient attendances with and without proce-
dures were assigned the appropriate unit costs from the
NHS Reference Costs publication [32] by treatment spe-
cialty. Inpatient care was costed using the Health
Resource Group 2017–2018 Reference Costs Grouper
software [33] before applying reference costs for each
category of stay, taken from the UK National Cost
Schedule [32]. Medications were costed by mapping
CPRD to British National Formulary codes [34] data and
multiplying the quantity prescribed by the unit costs
from the British National Formulary. Manual checks
were carried out to examine the validity of quantity,
strength and dosage of prescriptions.
Mean all-cause health-care costs per patient per year
were estimated for the pre- and post-diagnosis periods
for identified patients with SLE. Costs were examined
for 10 years after the index date as the sum of costs
by type of care (primary care, hospital inpatient, outpa-
tient and prescription drugs) in the respective year. For
patients with >12 months of pre-index disease-free
data, we considered 3 years before diagnosis as refer-
ence for post-diagnosis cost comparisons.
To account for inflation and variations in pricing over
time, 2017 unit costs were applied to all years from the
UK NHS perspective. Additional detail on the methods
used to estimate costs for each type of care is provided
in Supplementary Table S4, available at Rheumatology
Advances in Practice online.
Data analysis
We used means, standard deviations and frequencies to
describe the characteristics of patients with SLE overall
and by disease severity. We estimated unadjusted
means and the 25th, 50th (median) and 75th quartiles to
summarize annual counts by type of utilization, including
inpatient and outpatient hospital and primary care visits,
in addition to prescriptions. We estimated the unad-
justed mean all-cause health-care costs per patient per
year in the 3 years before the index date to 10 years af-
ter by type of care (primary care, inpatient, outpatient
hospital and prescription drugs) and by disease severity
(mild, moderate and severe SLE).
We used generalized estimating equations (GEEs) to
compare mean all-cause health-care costs in each year
with the reference year (3 years before the index date),
adjusting for age and disease severity. We used the
third year before diagnosis as a reference, to avoid dis-
tortion by the higher expected costs in the 24 months
preceeding formal SLE diagnosis. Specifically, previous
research has demonstrated that patients present with
symptoms that might not be recognized immediately; for
example, Al Sawah et al. [35] reported an average of
2.1 years between first lupus symptoms and seeking of
medical care. We then used a random-effects (random
intercepts) model to estimate patient-specific annual
trends in mean all-cause health-care costs, adjusting for
age and disease severity. Only the main effect from
these models (trend in costs) is shown, because the
effects of covariates were very similar to the ones from
the GEE models. All available years of data were in-
cluded for patients with variable amounts of pre-diagno-
sis and follow-up information. All analyses were




A total of 802 individuals with 12 months of pre- and
post-index data were identified, of whom 369 (46.0%)
had mild SLE, 345 (43.0%) moderate SLE and 88
(10.9%) severe SLE. Table 1 presents descriptive infor-
mation on patient characteristics, overall and by disease
severity (mild, moderate and severe). About 88% were
female, and the average age was 48.4 years. Patients
had an average of 5.2 years of follow-up data after diag-
nosis. Of these 802 patients, 682 (85%) had 3 years of
health records prior to the index diagnosis of SLE, and
569 (71%) had 3 years of follow-up data after
diagnosis.
Direct health-care utilization
The average number of primary care visits, inpatient
stays, outpatient visits and prescriptions in the year of
diagnosis was 28.4, 1.2, 8.8 and 46.9, respectively
(Fig. 1). For all types of health-care use, there was a
pattern of increasing utilization in the 3 years before di-
agnosis, with a peak during the year of diagnosis, after
which health-care utilization remained fairly constant
over 10 years of follow-up (Fig. 1; Supplementary Table
S5, available at Rheumatology Advances in Practice
online).
Mean all-cause direct health-care costs
The mean, unadjusted, all-cause health-care cost for
patients with SLE increased progressively in the 3 years
before diagnosis, and during the first year after diagno-
sis rose to £7532 (Table 2). The mean all-cause health-
care cost held relatively steady throughout 7 years of
follow-up. The highest health-care costs were observed
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in years 8–10 (from fewer patient numbers) reaching
£12 195 in year 10 (Table 2). The adjusted total mean an-
nual increase in all-cause health-care costs from 3 years
before the index date compared with each available
follow-up year, adjusted for age, sex, disease severity
and co-morbid conditions, followed a similar pattern. In
the year after diagnosis, adjusted costs reached £4476
(95% CI: £3809, £5092; P< 0.0001) and remained higher
in the years after diagnosis compared with the pre-diag-
nosis period (Table 2; Supplementary Table S6, available
at Rheumatology Advances in Practice online).
Direct health-care costs by type of encounter
Primary care utilization was the leading component of
health-care costs during the first year of diagnosis,
representing an unadjusted mean cost of £2682 (Fig. 2).
The proportion of health-care cost utilization attributable
to primary care and the other utilization categories
remained steady until year 6, after which the largest in-
crease in health-care costs was observed (Fig. 2).
All-cause direct health-care costs by disease
severity
All-cause health-care costs increased over time for
patients with severe and moderate SLE but remained
relatively flat over the study period for patients with mild
SLE. These unadjusted mean costs in the year of diag-
nosis were £14 125, £8323 and £5221, for severe, mod-
erate and mild SLE, respectively (Fig. 3). Adjusted mean
all-cause health-care costs were greater for patients










Female, n (%) 709 (88.4) 326 (88.4) 311 (90.1) 72 (81.8)
Age at index, mean (S.D.), years 48.4 (15.3) 47.1 (14.4) 48.2 (15.7) 53.9 (16.0)
Age, n (%)
18–44 years 348 (43.4) 169 (45.8) 152 (44.1) 27 (30.7)
45–64 years 321 (40.0) 149 (40.4) 134 (38.8) 38 (43.2)
65 years 133 (16.6) 51 (13.8) 59 (17.1) 23 (26.1)
Follow-up, years
Mean (S.D.) 5.2 (3.0) 5.0 (3.0) 5.6 (3.0) 4.7 (2.8)
FIG. 1 Health-care utilization by category from 3 years before to 10 years after the index date (Clinical Practice
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TABLE 2 Mean health-care costs from 3 years before to 10 years after the index date (Clinical Practice Research





per person per year, £a
Adjusted mean all-cause health-care
costs vs 3 years before indexb
Estimate, £a,c 95% CIs, £ P value
Before diagnosis
Year 3 (n¼682) 3250 (4475) – – – –
Year 2 (n¼735) 4171 (6760) 1020 654 1386 <0.0001
Year 1 (n¼802) 6114 (8183) 3058 2545 3571 <0.0001
After diagnosis
Year 1 (n¼802) 7532 (9634) 4476 3861 5092 <0.0001
Year 2 (n¼675) 6769 (11 502) 3898 3124 4672 <0.0001
Year 3 (n¼569) 6809 (12 325) 4172 3276 5069 <0.0001
Year 4 (n¼472) 6367 (10 028) 4043 3233 4854 <0.0001
Year 5 (n¼385) 6950 (11 442) 4950 3944 5957 <0.0001
Year 6 (n¼294) 6593 (8759) 4947 4014 5881 <0.0001
Year 7 (n¼229) 7614 (10 870) 6172 4889 7455 <0.0001
Year 8 (n¼158) 10 023 (14 807) 8506 6506 10 507 <0.0001
Year 9 (n¼109) 10 398 (17 777) 9239 6350 12 128 <0.0001
Year 10 (n¼66) 12 195 (20 286) 10 550 6592 14 508 <0.0001
aCosts are expressed in 2017 UK pounds. bPerson-time denominators were used to account for varying lengths of follow-
up for individual patients.cCalculated using generalized estimating equations to compare mean all-cause health-care costs
in each year with the reference year (3 years before the index date), adjusting for age and disease severity.
FIG. 2 Mean annual health-care costs by category before and after the index date (Clinical Practice Research
























































































Unadjusted costs are expressed in 2017 UK pounds. Costs were estimated using a health system perspective and in-
cluded direct medical resource use only. Other costs, such as out-of-pocket expenditure by patients and costs of in-
formal and formal caregiving, were not captured. GBP: UK pounds.
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with moderate vs mild SLE (£2786; 95% CI: £1737,
£3835; P< 0.0001) and with severe vs mild SLE
(£5207; 95% CI: £3277, £7138; P< 0.0001). Models of
individual trajectories of mean all-cause health-care
costs (Table 3) showed an increase of £616 (95% CI,
£560, £672) per year, controlling for age, sex and dis-
ease severity. The increased costs were most pro-
nounced among patients with severe SLE (£1228; 95%
CI, £981, £1476), followed by moderate (£788; 95%
CI, £699, £878) and mild SLE (£262; 95% CI, £194,
£330).
Discussion
Direct health-care costs increased gradually in the
3 years before diagnosis, with high costs in the year af-
ter diagnosis, which remained relatively stable for sev-
eral years, possibly reflecting the establishment of
treatment regimens. Among patients who remained in
the database, mean all-cause health-care costs rose
sharply in follow-up years 8–10. This might represent
costs associated with long-term SLE care and co-mor-
bid disease; however, this rise should be viewed with
caution given the smaller sample size in later years and
FIG. 3 Mean annual total health-care costs by disease severity before and after the index date (Clinical Practice











































































Unadjusted costs are expressed in 2017 UK pounds. SLE disease severity was classified as mild, moderate or severe
using an adapted claims-based algorithm that uses SLE-related conditions and medications. GBP: UK pounds.
TABLE 3 Change in total health-care costs per year by disease severity (Clinical Practice Research Datalink–Hospital
Episodes Statistics database, 2005–2017)
Group Change in all-cause
health-care costs/year, £a,b
95% CIs, £ P-value
All patients (n¼802) 616 560 672 <0.0001
Mild SLE (n¼369)c 262 194 330 <0.0001
Moderate SLE (n¼345)c 788 699 878 <0.0001
Severe SLE (n¼88)c 1228 981 1476 <0.0001
aCosts are expressed in 2017 UK pounds. bCalculated using random intercept patient-specific models. cSLE disease severity
was classified as mild, moderate or severe using an adapted claims-based algorithm that uses SLE-related conditions and
medications.
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might be explained by outlier cases (e.g. those with or-
gan damage as a result of SLE). Health-care costs in-
creased with increasing severity. Patients with moderate
or severe SLE consistently incurred greater all-cause
health-care costs over time compared with patients with
mild SLE during a 3-year pre-diagnosis period and after
diagnosis, until 10 years of follow-up; costs doubled for
patients with moderate and severe SLE, whereas the
cost for mild SLE did not increase. The increase in ad-
justed mean all-cause health-care costs per year were
4.7- and 1.6-fold higher among patients with severe SLE
compared with those with mild and moderate SLE,
respectively.
There are limited data evaluating health-care costs as-
sociated with SLE over time. The substantial health-care
costs found in the present study are consistent with
studies from other countries that have reported a signifi-
cant economic burden associated with SLE. A review of
articles published between 2007 and 2013 reported high
medical costs and high levels of unemployment and ab-
senteeism associated with the disease [36]. An earlier
review of 11 articles reported that average direct costs
per patient-year ranged from $3735 to $14 410 (2008 US
dollars), mostly driven by inpatient care [12]; in another
review of 14 studies, the direct annual costs were be-
tween $2214 and $16 685 (2010 US dollars) [15]. A re-
cent study also reported that the direct health-care
costs associated with SLE were $13 038 (2013 Canadian
dollars) [14]. Comparisons between the costs estimated
in our study and those estimated in previous studies
would need to account for the relevant currency ex-
change and inflation rates and should be made cau-
tiously, owing to differences in the methodology used to
estimate costs, in addition to structural differences in
the underlying health-care delivery landscape across
countries.
Our study also complements the limited literature on
costs of SLE in the UK, which has been based on small
samples. One cross-national comparison of patients in
the US, Canada and UK, the Tri-Nation study [37], relied
on self-reported data for 215 UK-based patients.
Another study consisted of 86 patients recruited from
four specialist rheumatology centres in England (the
LUCIE study) [38, 39]. Detailed data on inpatient and
specialist care were obtained from medical chart review
for a cohort of patients with prevalent SLE over a
follow-up period of 2 years. The LUCIE study was not
designed to track either the impact on cost of a nascent
diagnosis or the effect on costs over the medium to
long term. Furthermore, primary care costs were not
captured. We add to this literature by estimating costs
across all settings covered by the NHS in the UK for an
extended period before incident diagnosis of SLE and
following patients for as long as data were available,
10 years after diagnosis.
In contrast to studies from other countries [12, 14–16],
which found that the largest component of medical
costs associated with SLE was inpatient hospitalization,
we found that primary care utilization represented a
larger share of the mean all-cause health-care cost
compared with inpatient stays. This might reflect differ-
ences in care delivery, the generally lower costs of inpa-
tient care in the UK compared with the USA, or
differences among the costing methodologies used.
Prescription medications made up a substantial and
growing share of the mean all-cause cost over time in
our study. This might be attributable to an increasing
need to manage co-morbid conditions and/or the se-
quelae of SLE as the disease progresses.
Our study demonstrated an increase in adjusted mean
all-cause health-care costs over time, with the increase
in costs being most pronounced among patients with
severe SLE, followed by those with moderate SLE. This
is likely to reflect the extent of organ damage in these
patients. Greater organ damage has been associated
with increased health-care resource use [40]. Potentially,
cost savings could be achieved by earlier diagnosis and
treatment, including careful monitoring, to reduce the
onset of irreversible organ damage and the occurrence
of co-morbidities. This aligns with clinical guidelines that
stress the goal of treatment aimed at improving long-
term patient outcomes and quality of life, in addition to
preventing damage accrual [41].
Observational studies using routinely collected elec-
tronic health record data are subject to several limita-
tions, including the possibility of missing or misclassified
data. To reduce potential misclassification of SLE diag-
nosis, we required that an SLE diagnosis be confirmed
using an algorithm, modified from Nightingale et al. [23],
to identify additional criteria in the patient record. It is
possible to have underestimated the number of cases,
because patients without active disease might have
been excluded owing to lack of supporting data on
treatment in the medical record. Electronic health
records do not routinely include the information needed
to generate established scores for disease severity and
activity [23, 42]. However, we used a validated algorithm
to assign patients to mild, moderate and severe disease
categories in the year after index diagnosis [16, 43]. It is
possible, given the criteria used in the algorithm, that
we have underestimated the proportion of patients with
severe SLE and overestimated those with moderate and
mild disease. For example, one of the criteria for severe
disease is a prescription of prednisolone of >60 mg/day.
Other disease severity scores might use lower milligram
per day thresholds for severe disease [44]. However, our
analysis clearly shows an association between costs
and severity.
CPRD GOLD linkage data are available for only 50%
of contributing CPRD GOLD practices in the UK; there-
fore, health-care resource use is not available for all SLE
patients captured in the CPRD database. Our study in-
cluded health-care costs to the NHS only and did not in-
clude other societal costs, such as informal care (e.g. by
family members and friends), out-of-pocket costs for
non-prescription medications and other services not
covered by the NHS, and a range of non-health-care
costs, such as lost productivity. Other studies have
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found these indirect costs in individuals with SLE to be
much higher than the direct medical costs [45]. In addi-
tion, costs of biologics and drugs prescribed at specialty
centres are not captured in the CPRD database.
Together, these factors suggest that our results might
be an underestimation of the true SLE costs in the UK.
Finally, our estimates are based on the missing-at-
random assumption, implying that loss to follow-up was
not related to health-care costs. As in most longitudinal
studies, this assumption could not be tested directly,
because cost data on patients after they left the dataset
were not available. However, there is no reason to ex-
pect that leaving the dataset is associated with the se-
verity of SLE and, therefore, with health-care utilization
and cost of care.
Conclusions
Our findings suggest that the direct costs of health care
for patients with SLE in the UK are substantial and in-
crease in the years before and after diagnosis. Patients
with moderate or severe SLE consistently incur greater
all-cause health-care costs over time compared with
patients with mild SLE during the 3 years before and af-
ter diagnosis, up to 10 years. For all patients, health-
care costs gradually increase during the 3 years before
diagnosis, suggesting that patients might initiate
encounters with the health-care system in quest of a di-
agnosis. This study sheds light on the importance of dis-
ease management for the moderate to severe SLE
patient. Earlier diagnosis and treatment might reduce
disease severity and occurrence of co-morbidities and
the high health-care costs associated with SLE.
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